Mamedica is a start-up which was founded in 2021 and launched in 2022. We are one of just four clinics in the U.K. to have obtained licensing to prescribe and dispense medical cannabis (offering cannabis flower to oil.) Our clinic provides virtual consultations to patients who suffer from pain, psychiatry, neurology, palliative care and cancer-related conditions.
Our team of specialist doctors provide expert initial evaluation and aftercare support to make sure our service is stress-free, simple, safe, and effective. Medication is then delivered to patients via secure courier.
How did you come up with the idea for the company?
I first became aware of cannabis around 20 years ago however, it wasn’t until I spent time in California that I realised the potential it had to improve the lives of people who were on much stronger medications. It was a more personal experience which proved to be the catalyst for Mamedica.
In May last year, a good friend of mine alluded to the fact he was suffering from anxiety and depression for which he had obtained a private medical cannabis prescription, but the service he was receiving wasn’t as good as he would have liked. As soon as I heard that, I instantly got to work trying to understand the patient experience, and how it could be improved.
More from Interviews
- A Chat With Siyi Hao, Principal At Roland Berger On Europe’s AI Data Centre Developments
- Interview With Ravina Bhanot, Founder At One Labs+ On Her Experience Building An SME In The UK
- A Chat With Gianni Romano, Founder And CEO Of Clothink, On Bringing AI To Fashion Product Development
- A Chat With Eugene Zlotin, Founder And CEO Of Flamingo Compliance On Turning International Compliance Into A System That Spots Risks Early
- A Conversation With Oleksii Pimenov, Founder And Chief Software Engineer At SimBuster
- A Chat With Emmanuel Olarewaju David, CTO Of ProtonLabs Technology And US50 2026 Judge
- Investing Without Traditional Intermediaries: Interview With Przemysław Paweł Januszaniec, CEO Loanch
- Dear Mr. Prime Minister: Richard Clifford, VP Of Sales And Solutions At Salute
How has the company evolved over the last couple of years/months?
We welcomed our first patients in June this year which was a significant milestone. We’ve assembled a team made up of a diverse and passionate mix of specialist doctors, pharmacists and patient care coordinators focused on offering the best of what medical cannabis has to offer.
The journey from conception of idea, seeking the necessary regulatory approvals, to launching, has taken just over a year. In that time, we have secured £1 million in funding from private investors through Government incentive schemes (SEIS/EIS) and have successfully obtained licences from the Care Quality Commission and General Pharmaceutical Council to provide our services.
What can we hope to see from Mamedica in the future?
Most people are completely unaware that a service like ours exists. We’re here to provide education and insight into how medical cannabis can support patients across a number of conditions. Despite it becoming a legal pathway since 2018 we’ve got a long way to go in the U.K. in terms of spreading awareness on how to access medical cannabis.
Our focus for Mamedica is to become a leading healthcare provider. We want patients, caregivers, medical professionals and loved ones to know our service is a legitimate and accessible pathway to improving lives.
